Artigo Acesso aberto Revisado por pares

Trial of Deferiprone in Parkinson’s Disease

2022; Massachusetts Medical Society; Volume: 387; Issue: 22 Linguagem: Inglês

10.1056/nejmoa2209254

ISSN

1533-4406

Autores

David Devos, Julien Labreuche, Olivier Rascol, Jean‐Christophe Corvol, Alain Duhamel, Pauline Guyon Delannoy, Werner Poewe, Yaroslau Compta, Nicola Pavese, Evžen Růžička, Petr Dušek, Bart Post, Bastiaan R. Bloem, Daniela Berg, Walter Maetzler, Markus Otto, Marie‐Odile Habert, Stéphane Lehericy, Joaquim J. Ferreira, Richard Dodel, Christine Tranchant, Alexandre Eusébio, Stéphane Thobois, Ana Marqués, Wassilios G. Meissner, Fabienne Ory‐Magne, Uwe Walter, Rob M.A. de Bie, Miguel Gago, Dolores Vilas, Jaime Kulisevsky, Cristina Januário, Miguel Vilhena Soares Coelho, Stefanie Behnke, Paul Worth, Klaus Seppi, Thavarak Ouk, Camille Potey, Céline C. Leclercq, Romain Viard, Grégory Kuchcinski, Renaud Lopes, Jean‐Pierre Pruvo, Pascal Pigny, Guillaume Garçon, O. Simonin, Jessica Carpentier, Anne‐Sophie Rolland, Dag Nyholm, Christoph Scherfler, Jean‐François Mangin, Marie Chupin, Régis Bordet, David T. Dexter, Caroline Fradette, Michael Spino, Fernando Tricta, Scott Ayton, Ashley I. Bush, Jean-Christophe Devedjian, James A. Duce, Ioav Cabantchik, Luc Defebvre, Dominique Deplanque, Caroline Moreau,

Tópico(s)

Folate and B Vitamins Research

Resumo

Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its effects on disease progression are unclear.

Referência(s)